Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.09 +0.08 (+0.31%)
Official Closing Price Updated: 7:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
35 36 Next >
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy
From Pfizer Inc.
Via Business Wire
Lifestyle Drugs Market to See Huge Growth by 2028 : Alkermes, AstraZeneca, Pfizer, BMS
Lifestyle Drugs Comprehensive Study by Type (Depression, Dermatology, Sexual dysfunction, Obesity), Application (Children, Adults, Senior Citizens), Form (Tablets, External Use, Injection) Players and... 
Via SBWire
Exposures Product Safety
AI for Pharma and Biotech Market May Set Massive Growth by 2030
Get a view on AI for Pharma and Biotech Market sales by marketing channels. Target important market by region and tap important dynamics of this industry. 
Via SBWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
MarketBeat Week in Review – 7/17 - 7/21
Investor sentiment remains strong but upcoming tech earnings and an expected interest rate hike may provide more clarity on the short-term outlook for stocks 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Pfizer Inc. (NYSE: PFE) is One of Monday Morning’s Most Active Stocks
Via Investor Brand Network
Exposures COVID-19
Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility
From Pfizer Inc.
Via Business Wire
3 Undervalued Large-Cap Stocks That Won't Be for Long
Buying undervalued stocks that have unrealized catalysts will rarely disappoint investors who have the discipline to hold them over time. 
Via MarketBeat
Exposures COVID-19
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
From Pfizer Inc.
Via Business Wire
MarketBeat Week in Review – 7/10 - 7/14
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Pfizer Just Invested $25 million In This Biotech
Pfizer's investment propels Caribou Biosciences' stock and fuels optimism for its lead candidates: CB-010 and CB-011, both currently in phase 1 trials. 
Via MarketBeat
Pfizer (NYSE: PFE) Invests $25 Million in Caribou Biosciences (NASDAQ: CRBU)
On July 6, 2023, Caribou Biosciences, Inc., a significant player in the field of CRISPR genome-editing biopharmaceuticals, announced a $25 
Via Spotlight Growth
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Collaboration expands Carrick’s clinical-stage Oncology program 
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
From Caribou Biosciences, Inc.
Via GlobeNewswire
Chronic Plaque Psoriasis Market and Epidemiology 2032: Treatment Therapies, FDA Approvals, Companies and Patient based Forecast by DelveInsight | Dermavant Sciences, Pfizer, Arcutis Biotherapeutics
Via AB Newswire
Exposures Product Safety
Hemophilia A Market expected to rise | Companies – Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix pharmaceutical
Via AB Newswire
Immunome (NASDAQ: IMNM) and Morphimmune Announce Merger to Develop Best-in-Class Targeted Cancer Therapies
Via Spotlight Growth
Exposures Product Safety
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
From Pfizer Inc.
Via Business Wire
Pleural Effusion Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies – Lung Therapeutics, Carefusion, Pfizer, Roche
Via AB Newswire
Activision Blizzard Shares up 1.83% Amid Regulators' Blunders
Shares of Microsoft Corp. (NASDAQ: MSFT) declined 1.92% on June 26, more than the broader market, while Activision Blizzard Inc. (NASDAQ: ATVI) rose 1.83%. The S&P 500 declined 0.41% in the session. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Lipodystrophy Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Regeneron, Ionis, Pfizer, Amunix, Zydus Cadila, Galmed, CombiGene, Carmot Therapeutics
Via AB Newswire
Exposures Product Safety
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
From Pfizer Inc.
Via Business Wire
Non Muscle Invasive Bladder Cancer Pipeline and Clinical Trials Analysis 2023 (Updated): 25+ Companies are working to improve the Treatment of Space | Pfizer, Janssen, Protara, Merck
Via AB Newswire
Duchenne Muscular Dystrophy Market expected to rise | Companies – Sarepta Therapeutics, PTC Therapeutics, Nippon Shinyaku, Pfizer, Santhera Pharmaceuticals/ReveraGen BioPharma, Taiho Pharmaceutical
Via AB Newswire
Multiple myeloma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Alliance Foundation Trials, LLC, Celgene
Via AB Newswire
Exposures Product Safety
Prader-Willi Syndrome Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies | Companies – Soleno Therapeutics, Levo Therapeutics, Pfizer, Novo Nordisk
Via AB Newswire
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t 
Via MarketBeat
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
From Pfizer Inc.
Via Business Wire
Leiomyosarcoma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies |Companies – Pfizer, PTC Therapeutics, GlaxoSmithKline, AstraZeneca, Merck
Via AB Newswire
Neuroendocrine Tumor Pipeline Drugs 2023 (Updated), FDA Approvals, Clinical Trials, MOA, ROA | MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, and others
Via AB Newswire
Exposures Product Safety
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.